血管生成素样蛋白4与新血管性年龄相关性黄斑变性玻璃体腔注射雷珠单抗治疗反应相关
研究纳入新血管性年龄相关性黄斑变性(AMD)患眼30只与白内障手术对照眼32只,检测房水血管生成素样蛋白4(ANGPTL4)与血管内皮生长因子(VEGF)。AMD组基线ANGPTL4与VEGF均高于对照组(均P<0.001),首次注射后4周VEGF显著下降(P<0.001)。基线ANGPTL4与基线及12个月病灶面积相关(分别P<0.05),并与12个月内抗VEGF注射频率相关(P=0.008)。
要点
- AMD组基线房水ANGPTL4与VEGF均高于白内障对照组(均P<0.001)。
- 首次雷珠单抗注射后4周,AMD组VEGF显著下降(P<0.001)。
- 基线ANGPTL4与基线及12个月病灶面积相关,并与12个月注射频率相关(P=0.008)。
核心结论
- 房水ANGPTL4水平与病灶面积及抗VEGF治疗频率相关,ANGPTL4可能是新血管性AMD的潜在诊断和/或治疗生物标志物。
研究设计与样本
- 对照与研究组分别由连续接受老年性白内障手术或玻璃体腔雷珠单抗注射的初治新血管性AMD患者组成;AMD组接受3次每月雷珠单抗注射后按需每月治疗至少12个月。
- 在基线与首次注射后4周测量房水ANGPTL4与VEGF;AMD组在基线与12个月测量最佳矫正视力、荧光素血管造影病灶面积与中心子区厚度。
主要发现
- AMD组(30眼)基线房水ANGPTL4与VEGF水平均高于对照组(32眼)(均P<0.001)。
- 首次注射后4周,AMD患者VEGF显著下降(P<0.001)。
- 基线ANGPTL4与基线及12个月病灶面积相关(分别P<0.05),并与12个月内抗VEGF注射频率相关(P=0.008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD). METHODS: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naïve neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months. Aqueous ANGPTL4 and vascular endothelial growth factor (VEGF) were measured at baseline and 4 weeks after the first injection. In the AMD group, best-corrected visual acuity, lesion area by fluorescein angiography, and central subfield thickness were measured at baseline and at 12 months. RESULTS: The AMD group (30 eyes) had higher baseline aqueous ANGPTL4 and VEGF levels than those of the control group (32 eyes) (both P < 0.001). Four weeks after the first injection, VEGF in the patients with AMD had dropped significantly (P < 0.001). Baseline ANGPTL4 correlated with the lesion area at baseline and at 12 months (P < 0.05, respectively), and also correlated with the frequency of anti-VEGF injections during 12 months (P = 0.008). CONCLUSION: Aqueous ANGPTL4 levels correlated with the lesion area and anti-VEGF treatment frequency. Angiopoietin-like 4 may be a potential diagnostic and/or therapeutic biomarker in the neovascular AMD.
引用
- Kim JH, Shin JP, Kim IT, et al. ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2018. PMID: 28151839. doi:10.1097/IAE.0000000000001554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。